A study to evaluate the safety and the processing of GDC-0829 by the body in healthy participants
- Conditions
- Healthy volunteersNot Applicable
- Registration Number
- ISRCTN18049481
- Lead Sponsor
- F. Hoffmann-La Roche Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ongoing
- Sex
- All
- Target Recruitment
- 104
1. Age 18 - 65 years at the time of signing the Informed Consent Form
2. Body mass index (BMI) =18.5 and <30 kilograms per metre squared (kg/m^2)
3. Ability to comply with the study protocol
1. Pregnancy or breastfeeding, or intention of becoming pregnant during the study or within 28 days after the final dose of study drug
2. Planned procedure or surgery during the study
3. Positive human immunodeficiency virus (HIV) test at screening
4. Positive hepatitis B surface antigen (HBsAg) test at screening
5. Positive hepatitis C virus (HCV) antibody test at screening
6. Any serious medical condition or abnormality in clinical laboratory tests
7. History of malignancy within 5 years prior to screening
8. Acute illness within 14 days prior to screening
9. Vaccination within 14 days prior to initiation of study drug
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method